Kineta Wins $4 Million Contract With National Institutes of Health

Seattle biotech company Kineta just won a $4 million contract with the National Institutes of Health to develop an immunotherapy treatment targeting infectious diseases like dengue fever, Ebola, and the flu.
According to an article from the Puget Sound Business Journal:

Kineta develops drugs for chronic pain, autoimmune and infectious diseases. The funding will be used to bring a specific drug candidate to the pre-clinical stage, with the goal of eventually advancing it through clinical trials.

What’s unique about the drug Kineta is developing that, unlike a typical anti-viral, this won’t focus on killing the virus. Instead, the immunotherapy drug — taken as a pill — flips a switch in your immune system if you have the flu, for example. The drug then boosts your immune system response and keeps the switch flipped on until you overcome the disease.

 
Click here to read the full article on the Puget Sound Business Journal.